J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner
- Editor
- May 19
- 1 min read
Whats Happening:
J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm of J.P. Morgan Asset Management, has appointed Dashyant Dhanak, Ph.D., as Venture Partner. Dr. Dhanak, a seasoned pharmaceutical R&D expert with over 30 years of experience, will leverage his expertise to build and grow companies within the fund's portfolio.
Key Moves:
J.P. Morgan Life Sciences Private Capital appoints Dashyant Dhanak as Venture Partner
Dr. Dhanak brings over 30 years of pharmaceutical R&D experience
He will focus on building and growing companies within the fund's portfolio
By The Numbers:
J.P. Morgan Asset Management has $3.7 trillion in assets under management as of 3/31/2025
JPMorgan Chase had $4.4 trillion in assets as of 3/31/2025
JPMorgan Chase had $351 billion in stockholders' equity as of 3/31/2025
Key Quotes:
"Dr. Dhanak has a proven track record of building and establishing leading biotech companies with scientific and operational excellence," said Dr. Stephen Squinto, CIO of Life Sciences Private Capital.
"We are excited to welcome Dr. Dhanak to the team, and know he will play an essential role as our platform continues to grow."
Bottom Line:
The appointment of Dr. Dashyant Dhanak as Venture Partner strengthens J.P. Morgan Life Sciences Private Capital's ability to identify and nurture promising biotech companies. His extensive experience in pharmaceutical R&D will be crucial in driving innovation and growth within the fund's portfolio, potentially leading to significant advancements in the life sciences sector.
Comments